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From a community-based survey conducted in Angola, 468 individuals aged 40 to 64 years and not using drug therapy were
evaluated according to the World Health Organisation STEPwise Approach to Chronic Disease Risk Factor Surveillance. Using
data from tobacco use, blood pressure, blood glucose, and total cholesterol levels, we estimated the 10-year risk of a fatal or nonfatal
major cardiovascular event and computed the proportion of untreatedparticipants eligible for pharmacological treatment according
to clinical values alone and total cardiovascular risk. The large majority of participants were classified as having a low (<10%)
10-year cardiovascular risk (87.6%), with only 4.5% having a high (≥ 20%) cardiovascular risk. If we consider the single criteria
for hypertension, 48.7% of the population should be considered for treatment. This value decreases to 22.0% if we apply the risk
prediction chart. The use of hypoglycaemic drugs does not present any differences (19.0% in both situations). The use of lipid-
lowering drugs (3.8%) is only recommended by the risk prediction chart. This study reveals the need of integrated approaches for
the treatment of cardiovascular disorders in this population. Risk prediction charts can be used as a way to promote a better use of
limited resources.
1. Introduction
Cardiovascular diseases (CVD) caused 17.9 million deaths
worldwide in 2015, a number that has increased globally by
12.5% since 2005, with almost 80% of these deaths occurring
in low and middle-income countries [1]. Their common
occurrence and associated mortality, loss of independence
and productivity, impaired quality of life, and social and
economic costs are compelling reasons for public health
concern globally [2].
The epidemiology of CVD is distinctly different in sub-
Saharan Africa (SSA), compared to the rest of the world,
where an unprecedented decline in mortality and a corre-
sponding increase in the life expectancy at birth are shifting
the epidemiological landscape of the region [3]. Countries in
this region, where Angola is located, face a double burden as
they struggle to cope with noncommunicable and infectious
diseases associated with lack of socioeconomic development
[3].
In 1990 the percentage of deaths by CVD in the region
was 7.5% (the fourth cause of death), rising to 11.2% in 2015,
being the third cause of mortality [4].Myocardial infarctions,
together with strokes, were responsible for 10.8% of deaths
among females and 8.6% in males, in 2015 in SSA [4]. This
represents an increase in mortality of 38.0% for stroke and
52.1% for myocardial infarction in both sexes, since 1990
[4], revealing a rising trend of CVD in SSA. The estimates
made for Angola follow the same pattern, with strokes being
responsible for 5.4% and myocardial infarction for 4.7% of
all deaths, in 2015, the fourth and sixth cause of mortality in
Angola, respectively [4].
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Risk factors for CVD are shared with the majority of
noncommunicable diseases and are due to exposure to
behavioural risk factors: tobacco and alcohol consump-
tion, unhealthy diet, and physical inactivity, individually
modifiable. These unhealthy behaviours influence metabolic
pathways and ultimately result in intermediate risk factors:
obesity, hypertension, diabetes, and dyslipidaemia [5–7].
Common approaches that address behavioural and
metabolic risk factors, which often coexist in the same person
and act synergistically to increase an individual’s total risk, are
proven effective for prevention [6, 7], but in some settings,
the risk factors are tackled one-by-one, without a common
strategy. To design the right strategy for an individual, it
is important to realise his/her “global risk” of developing
CVD [7–9]. The World Health Organization (WHO) and
the International Society of Hypertension (ISH) created a
risk prediction chart [8], which can be applied in different
populations.
In this short report, we aimed to quantify the proportion
of individuals eligible for pharmacological treatment for
hypertension, diabetes, and hypercholesterolemia according
to single risk factor and total cardiovascular risk approaches,
according to the WHO-ISH risk prediction chart.
2. Materials and Methods
The present report is a subset analysis from CardioBengo,
a community-based study conducted in the catchment area
of the Dande-Health Demographic Surveillance System
(Dande-HDSS), located in the Dande Municipality, in Bengo
Province, Angola [10]. This survey, done between September
2013 and March 2014, constitutes a larger baseline on cardio-
vascular risk factors [11], using the methodology proposed
by the WHO STEPwise approach to Surveillance (STEPS)
to Chronic Disease Risk Factor manual (core and expanded
version 3.0) [12].
2.1. Sample Characterization. The subset of individuals from
the CardioBengo study considered for this analysis follows
the WHO-ISH risk prediction chart criteria of application
[8]. The initial CardioBengo sample was made by 2,484
individuals (15 to 64 years old), drawn as a representative sex-
and age-stratified random sample from the Dande-HDSS
population database as previously described [11, 13].
The WHO-ISH risk prediction chart criteria of applica-
tion [8] only consider individuals aged 40 or older. In the
initial set, only 688 participants are aged above 40 years.
From this group, 123 were excluded due to missing infor-
mation in any of the parameters considered in the WHO-
ISH risk prediction chart (current smoking status, systolic
blood pressure, total blood cholesterol, and diabetes), and
another 97 were excluded because theywere already receiving
pharmacological treatment for any of the three conditions
(hypertension, diabetes, and hypercholesterolaemia). In this
way, the final sample consists of 468 participants.
2.2. Data Collection. Participants were evaluated by trained
interviewers and certified health professionals. As previ-
ously described in the CardioBengo study protocol [11],
information on age and tobacco consumption was collected
through an interview, and blood pressure and all clinical
measurements (measured only in participants with overnight
fasting) were obtained with the use of point of care devices,
namely, automatic sphygmomanometer OMRON M6 Com-
fort (OMRON Healthcare Europe BV, Hoofddorp, Nether-
lands); blood glucose meter ACCU-CHEK Aviva (Roche
Diagnostic, Indianapolis, USA); and ACCUTREND Plus
(Roche Diagnostic, Indianapolis, USA) with ACCUTREND
CHOLESTEROL reactive strips (Roche Diagnostic, Indi-
anapolis, USA) [11].
2.3. Prediction Methods and Eligibility for Pharmacological
Treatment. The WHO-ISH prediction chart for the Africa
D region was used to classify each participant regarding
the individual absolute cardiovascular risk [8], based on sex
(male or female), age (40–49, 50–59 and ≥ 60 years), cur-
rent smoking status (nonsmoker or smoker), systolic blood
pressure (SBP) (120-139, 140–159, 160–179, and ≥ 180mmHg),
total blood cholesterol (4, 5, 6, 7, and 8mmol/l), and diabetes
(presence or absence, considering the WHO cut point of
6.9mmol/l [14]).
TheWHO-ISHprediction charts estimate the 10-year risk
of a fatal or nonfatal major cardiovascular event (myocardial
infarction or stroke) expressed in five categories—≤10%
(low), 10–19% (moderate), 20–29% (high), and ≥30% (very
high)—in people who do not have established cardiovascular
diseases [8].
The eligibility for treatment with antihypertensive, hypo-
glycaemic, or lipid-lowering drugs was defined according
to the WHO guidelines for assessment and management
of cardiovascular risk [8]. Also, eligibility for treatment
according to the single risk factor approach was considered:
for antihypertensive drug use SBP of ≥140mmHg [15, 16]; for
hypoglycaemic drug use fasting blood glucose >6.9mmol/l
[14]; and for lipid-lowering drugs use a total blood cholesterol
level ≥8mmol/l [9].
2.4. Statistical Analysis. Data were double entered into a
PostgreSQL database and imported into SPSS version
23 (IBM, New York, USA) for data analysis. Descriptive
data are reported as absolute frequencies and percentages.
We estimated the proportion of participants classified in
different categories of total cardiovascular risk, as well as the
proportion of subjects eligible for pharmacological treatment
(according to the different criteria), by sex.We consider a 95%
confidence interval (95% CI) for all proportions calculated.
2.5. Ethical Approval. All procedures performed in this
study were in accordance with the standards of the Ethics
Committee of the Angolan Ministry of Health and with the
1964 Helsinki declaration and its later amendments. Written
informed consent was obtained from all participants.
3. Results
The majority of the population in this study was female
(69.7%) following the structure of theDande-HDSS [10], with
17.9% of the population aged above 60 years. Smoking was
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Table 1: Characteristics of the participants and prevalence by sex.
Total (n = 468) Female (n = 326) Male (n = 142)
% (95% CI) % (95% CI) % (95% CI)
Age (years)
40-49 36.3 (32.1-40.8) 35.0 (30.0-40.3) 39.4 (31.7-47.6)
50-59 45.7 (41.2-50.2) 47.9 (42.5-53.3) 40.8 (33.1-49.0)
≥ 60 17.9 (14.7-21.6) 17.2 (13.5-21.7) 19.7 (14.0-27.0)
Current smoking status
Non-smoker 89.3 (86.2-91.8) 92.6 (89.2-95.0) 81.7 (74.5-87.2)
Smoker 10.7 (8.2-13.8) 7.4 (5.0-10.8) 18.3 (12.8-25.5)
Systolic blood pressure (mmHg)
120-139 51.3 (46.8-55.8) 47.5 (42.1-52.9) 59.9 (51.7-67.6)
140-159 26.7 (22.9-30.9) 26.7 (22.2-31.8) 26.8 (20.2-34.6)
160-179 14.3 (11.4-17.8) 16.6 (13.0-21.0) 9.2 (5.5-15.1)
≥ 180 7.7 (5.6-10.4) 9.2 (6.5-12.8) 4.2 (1.9-8.9)
Total blood cholesterol (mmol/l)
4 55.6 (51.1-60.0) 52.1 (46.7-57.5) 63.4 (55.2-70.9)
5 27.1 (23.3-31.3) 26.7 (22.2-31.8) 28.2 (21.4-36.1)
6 13.0 (10.3-16.4) 15.0 (11.5-19.3) 8.5 (4.9-14.2)
7 4.3 (2.8-2.8) 6.1 (4.0-9.2) 0
8 0 0 0
Diabetesa
Absence 81.0 (77.2-84.3) 81.6 (77.0-85.4) 79.6 (72.2-85.4)
Presence 19.0 (15.7-22.8) 18.4 (14.6-23.0) 20.4 (14.6-27.8)
With SBP >140 mmHg and Diabetes 9.8 (7.4-12.8) 9.5 (6.8-13.2) 10.6 (6.5-16.7)
aFasting blood glucose ≥6.9 mmol/l.
more frequent among men (18.3% versus 7.4% in women)
with almost half the population (48.7%) presenting a SBP
≥140mmHg, with a higher occurrence in women (52.5%
versus 40.1% inmen). None of the individuals presented total
blood cholesterol >8mmol/l, with only women presenting
values >7mmol/l (6.1%). The prevalence of diabetes was
similar among men and women (18.4% in women and 20.4%
in men), with almost 10% of the population having both SBP
≥140mmHg and diabetes (Table 1).
Most of the participants (87.6%) were classified as having
low (<10%) 10-year cardiovascular risk.The frequencies were
7.9%, 2.6%, and 1.9% for the cardiovascular risk categories
10–19 (moderate), 20–29 (high), and ≥30% (very high),
respectively. Women presented higher frequencies than men
in all cardiovascular risk categories above the moderate level
and the total cardiovascular risk increased with age (Table 2).
Considering only the criteria of SBP ≥140mmHg, 48.7%
of the population should be considered for treatment with
antihypertensive drugs, but if we apply theWHO/ISH criteria
based on the prediction chart, this number will decrease by
more them half to 22.0%. On the other hand, the use of lipid-
lowering drugs is not considered for any individual by the
singular criteria, but if we apply the prediction chart, this
number rises to 3.8% (Table 3).
4. Discussion
Only 4.5% of the population was classified as having at
least a high (≥20%) cardiovascular risk. These results are
in accordance with those described in other populations
of the continental sub-Saharan Africa, namely, 3.7% in
Mozambique [17] and 5% in Nigeria [18], or in other low
and middle-income countries in Asia (4.9% in rural India,
1.3% in Cambodia, 2.3% in Malaysia, and 6% in Mongolia)
[19, 20]. In all these surveys, the accumulation of risk factors
exists in different levels. In this analysis, almost one-tenth of
the population accumulates at least two major risk factors
(hypertension and diabetes).
This raises additional concerns when we analyse this
subset of results together with the values found in the
CardioBengo population aged 16 to 64 years: a prevalence
of hypertension of 18.0%, diabetes of 9.2%, and hypercholes-
terolaemia of 4.0%, with a low awareness and control levels
[13]. The CVD are present in this population, but this does
not imply that the health systems in the region are ready to
face with this growing reality.
According to the WHO guidelines for assessment and
management of cardiovascular diseases [8], at least one-
quarter of the participants in this report would be eligible
for treatment with antihypertensive drugs, whereas if only
the single criteria were applied for hypertension, almost
half would be considered for pharmacological treatment.
Even if some discussion is possible about the applica-
bility of pharmacological treatment with a SBP of 140,
the specific behaviour of blood pressure in black individ-
uals (as the population observed) should be considered
[16].
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Table 2: Distribution of 10-year risk of a fatal or nonfatal major cardiovascular event, according to sex and age.
Total, % (95% CI)
≤10% 10-19% 20-29 % ≥30%
Low Moderate High Very High
40-49 years 34.2 (30.0-38.6) 1.3 (0.6-2.8) 0.6 (0.2-1.9) 0.2 (0.0-1.2)
50-59 years 40.6 (36.2-45.1) 3.6 (2.3-5.7) 0.6 (0.2-1.9) 0.9 (0.3-2.2)
≥ 60 years 12.8 (10.1-16.2) 3.0 (1.8-5.0) 1.3 (0.6-2.8) 0.9 (0.3-2.2)
Total 87.6 (84.3-90.3) 7.9 (5.8-10.7) 2.6 (1.5-4.4) 1.9 (1.0-3.6)
Female, % (95% CI)
≤10% 10-19% 20-29 % ≥30%
Low Moderate High Very High
40-49 years 32.5 (27.7-37.8) 1.5 (0.7-3.5) 0.6 (0.2-2.2) 0.3 (0.1-1.7)
50-59 years 41.7 (36.5-47.1) 4.0 (2.3-6.7) 0.9 (0.3-2.7) 1.2 (0.5-3.1)
≥ 60 years 11.7 (8.6-15.6) 3.1 (1.7-5.6) 1.8 (0.8-4.0) 0.6 (0.2-2.2)
Total 85.9 (81.7-89.3) 8.6 (6.0-12.1) 3.4 (1.9-5.9) 2.1 (1.0-4.4)
Male, % (95% CI)
≤10% 10-19% 20-29 % ≥30%
Low Moderate High Very High
40-49 years 38.0 (30.5-46.2) 0.7 (0.1-3.9) 0.7 (0.1-3.9) -a
50-59 years 38.0 (30.5-46.2) 2.8 (1.1-7.0) -a -a
≥ 60 years 15.5 (10.5-22.3) 2.8 (1.1-7.0) -a 1.4 (0.4-5.0)
Total 91.5 (85.8-95.1) 6.3 (3.4-11.6) 0.7 (0.1-3.9) 1.4 (0.4-5.0)
aNo individuals in this category.
Table 3: Frequencies of individuals who require pharmacological treatment by sex.
Single risk criteria Considering WHO/ISHa risk prediction
Total, % Female, % Male, % Total, % Female, % Male, %
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Antihypertensive drugs 48.7 52.5 40.1 22.0 25.8 13.4
(44.2-53.2) (47.0-57.8) (32.4-48.4) (18.5-26.0) (21.3-30.8) (8.7-20.0)
Lipid-lowering drugs -b -b -b 3.8 4.9 1.4
(2.4-6.0) (3.0-7.8) (0.4-5.0)
Hypoglycaemic drugs 19.0 18.4 20.4 19.0 18.4 20.4
(15.7-22.8) (14.6-23.0) (14.6-27.8) (15.7-22.8) (14.6-23.0) (14.6-27.8)
aWorld Health Organization/International Society of Hypertension.
bNo individuals in this category.
Theuse of theWHO-ISH risk prediction chart has already
been proven as more cost effective than other approaches
that make treatment decisions based on individual risk factor
thresholds only, especially for hypertension management
[7, 21–23]. In a South-African study, different strategies for
initiation of drug treatment were tested, and the conclusion
points to the fact that hypertension treatment based on the
total cardiovascular risk is more effective at saving lives and
less costly than those based only on the BP level [24].
In this prediction chart, we included the total choles-
terol measurement; however, the WHO-ISH chart offers the
possibility of not using this measurement [8]. The use of
laboratory (or point of care) assessment in low-resource
settings is dispensable, avoiding additional costs to the system
without losing a significant predictive power or introducing
an overconsumption of drugs, allowing for a better targeting
of resources to those who are more likely to develop CVD
[25, 26].
The high percentage of individuals that requires pharma-
cological treatment for diabetes (19.0%, very similar between
gender) is alarming, considering the fact that diabetes alone
is a very important health condition, but also an important
risk factor for CVD; adults with diabetes have a two or three
times higher rate of CVD than adults without diabetes [8, 27].
Health promotion initiatives such as smoking cessation
and individual advisement on specific lifestyle and diet
control are also strategies necessary to align with the use of
pharmacological treatments. Even if some of the proposed
methodologies (statins for hypercholesterolemia, for exam-
ple) cannot be easily applied due to the steady supply of
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drugs, changes to personal lifestyle should be encouraged,
with good results in the decrease of the global cardiovascular
risk [18, 21, 22].
The focus of targeting high-risk people through a total
cardiovascular risk approach instead of a single risk factor
approach reduces health care expenditure by reducing drug
costs [18]. However, to diminish CVD burden in the entire
population in a sustainable way, wider interventions are
needed.The focus should be on the primary healthcare, where
the majority of the individuals have access, allowing for the
promotion of opportunistic screening of CVD risk factors
and patient registration and tracking, with a better use of
available resources [23].
The findings in this report should be interpreted cau-
tiously. The study was conducted only at a district-level,
and due to the criteria of application of the WHO-ISH risk
prediction chart the sample size was small. Even with these
limitations, this report adds evidence to the emerging public
health issue of CVD, especially in older individuals, and
provides additional information on the impact of the use of
risk prediction charts.
5. Conclusion
The use of the WHO-ISH guidelines for cardiovascular risk
prediction reduces the population eligible for pharmacolog-
ical treatment, giving prominence to an integrated approach
based on lifestyle changes. This may sound appropriate to a
low-resource setting, but the low education level of this pop-
ulation and the lower ability in older individuals for altering
behaviours are factors to consider in future interventions.The
training of health professionals and raising awareness may be
the starting point to tackle CVD in this population, where the
use of these charts can have a role to play in the wise use of
resources available.
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